NCT02563327View on ClinicalTrials.gov

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

PHASE3CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

May 30, 2016

Primary Completion Date

August 30, 2021

Study Completion Date

August 30, 2021

Conditions
Tuberculosis
Interventions
DRUG

Rifapentine

A rifamycin with activity against Mycobacterium tuberculosis

DRUG

Moxifloxacin

A fluoroquinolone

DRUG

Rifampin

A rifamycin with activity against Mycobacterium tuberculosis

DRUG

Isoniazid

An anti-tuberculosis agent

DRUG

Pyrazinamide

An anti-tuberculosis agent

DRUG

Ethambutol

An anti-tuberculosis agent

DIETARY_SUPPLEMENT

Pyridoxine

An essential vitamin

Trial Locations (3)

Unknown

University of Texas Health Science Center at, San Antonio

Joint Clinical Research Centre/ Makerere Univ Med Sch, Kampala

National TB Program, Hanoi

All Listed Sponsors
collaborator

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK

lead

Centers for Disease Control and Prevention

FED

NCT02563327 - Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis | Biotech Hunter | Biotech Hunter